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Background: Despite progress in the management of 
invasive meningococcal disease (IMD) it causes sig-
nificant mortality and sequelae. Aim: This study aims 
to describe the epidemiology and clinical characteris-
tics of IMD in Cyprus and discuss the current immuni-
sation programmes. Methods: This is a retrospective 
study of all cases of IMD notified to the Ministry of 
Health between 2004 and 2018. Demographic, epi-
demiological, clinical and microbiological data were 
collected when a new case was notified. Risk factors 
associated with mortality were investigated using 
univariable logistic regression. Results: 54 cases of 
IMD were recorded, an overall incidence of 0.4 cases 
per 100,000 population. The incidence rate was high-
est among infants (7.2/100,000) and adolescents 
(1.4/100,000). Case fatality rate was 10.4%. Serogroup 
B accounted for 24 of 40 cases caused by known sero-
group. Serogroups W and Y comprised nine cases and 
were responsible for most fatal cases. Serogroup C was 
the cause in only four cases. There was an increase in 
the odds of death with increasing age, while the pres-
ence of meningitis in the clinical picture was found to 
be associated with lower odds of death. Conclusion: 
Despite the low incidence of IMD in Cyprus, it remains 
an important cause of morbidity and mortality. 
Serogroup B is the most frequent serogroup, while 
incidence of serogroups W and Y is rising. Monitoring 
new cases and yearly evaluation of the immunisation 
programmes by the National Immunization Technical 
Advisory Group (NITAG) is essential for successful con-
trol of the disease.
Introduction
Meningococcal disease is a potentially severe bacte-
rial infection caused by  Neisseria meningitidis,  often 
referred to as meningococcus.  Neisseria men-
ingitidis  colonises the nasopharynx of healthy 
individuals. The frequency of colonisation is ca 5–10% 
in healthy adults and up to 25% in adolescents [1]. In 
addition to colonisation,  N. meningitidis  can cause 
invasive disease, the most frequent forms of which 
are meningitis or bacteraemia/septicaemia or both 
[2,3]. Depending on the antigen of the polysaccharide 
capsule, meningococci are classified in 12 different 
serogroups. The most common serogroups are A, B, C, 
W, X and Y [3]. In Europe and the Americas, the most 
frequent serogroups causing disease are B and, less 
frequently, C, W and Y, whereas in Africa, A and X are 
most common [4,5].
Between 2004 and 2014, 49,269 meningococcal dis-
ease cases were recorded in European countries [5]. 
The mean annual incidence across Europe was 0.9 
cases per 100,000 population. The highest annual inci-
dence, 16 of 100,000, was found in infants younger 
than 1 year. Increased numbers of cases were also 
found in the age groups 1–4 years (4.9/100,000) and 
15–24 years (1.4/100,000). The most frequent sero-
groups were B and C, which represented 74%, and 
16% of all cases, respectively. Nevertheless, in recent 
years, B and C serogroups have followed a downward 
trend in many countries. In the European Centre for 
Disease Prevention and Control (ECDC) annual epide-
miological report for 2017, serogroup B caused 51% 
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of cases. An threefold increase was noted in the inci-
dence of serogroup W invasive meningococcal disease 
(IMD) between 2013 to 2017. Serogroup Y represented 
12% of the cases in 2017 [6].
The severity of meningococcal disease lies in the high 
mortality rates, which range between 5% and 15%, and 
the high risk of complications in survivors [7,8].
Different studies have reported risk factors associated 
with fatal outcome. Characteristically, high bacterial 
load is related to high mortality rate and high compli-
cation rates in the survivors [9]. Some other studies 
have further associated mortality by IMD with increas-
ing age, the presence of septicaemia without menin-
gitis and a period of less than 24 h between onset of 
symptoms and admission to hospital [10,11].
Introduction of vaccination against the different sero-
groups has significantly decreased the incidence of 
the disease. The first country to introduce the vaccine 
against serogroup C (MenC conjugate vaccine) was the 
United Kingdom (UK) in 1999. This intervention led to 
a decrease of more than 90% in laboratory-confirmed 
cases caused by serogroup C in immunised age groups 
[12,13]. Cases also decreased in other age groups by 
around two thirds as a result of reduction in carriage 
[14]. Similar decreases in the frequency of serogroup C 
disease were detected in a number of European coun-
tries who had introduced MenC vaccination in their 
national immunisation programmes [5]. Since 2009, 
there has been an increase in disease caused by sero-
groups W and Y in a number of European countries and 
the United States (US) [15,16]. Therefore, the quadriva-
lent conjugate vaccine against serogroups A, C, W and 
Y (MenACYW) replaced the MenC vaccine and has been 
administered mainly in adolescence in some countries 
[2,17].
Following the dramatic decrease in cases caused 
by serogroup C, serogroup B has become the most 
frequent cause of meningococcal disease in most 
European countries. In European countries, serogroup 
B represented 67.8% of laboratory-confirmed cases in 
2012 and 51% in 2017 [6,18]. In the UK between 2006/07 
and 2010/11, it accounted for 87% of meningococ-
cal disease cases, with the highest incidence among 
infants [19]. In September 2015, the UK was the first 
country to introduce a universal infant immunisation 
programme against serogroup B (4CMenB protein vac-
cine). This programme has led to a significant decrease 
in IMD attributable to serogroup B, with an effective-
ness of 82.3% in infants younger than 12 months [20].
During our study period, two different sectors of 
healthcare providers were operating in Cyprus, the 
public sector and the private sector, each with its 
own immunisation regimen, the public sector serv-
ing around 60% of the toddler population [21]. As a 
result, the MenC conjugate vaccine was introduced in 
two phases. In the private sector, it was introduced 
in early 2001, while in the programme of the public 
sector, free of charge to the whole population, it was 
introduced much later, at the end of 2006. According 
to the 3-yearly national vaccination coverage survey 
in toddlers, vaccination coverage of 17–24 months-old 
toddlers increased to high levels only after 2006 [22]. 
More precisely, the vaccination coverage for MenC vac-
cine increased from 49.2% in 2006 to 84.8% in 2012 
and since then, coverage rate in toddlers has remained 
high [21]. In 2014, the private sector replaced the MenC 
vaccine given in infancy with MenACYW, given in one 
dose at the age of 12 months. More recently, in January 
2017, the new 4CMenB vaccine was also introduced but 
only in the private sector. Since 2019, both immunisa-
tion schemes have been integrated and MenACWY is 
given to all population at the age of 12 months.
In Cyprus, there are no published epidemiological data 
on the incidence and mortality of meningococcal dis-
ease in the population except as part of the annual 
reports by the ECDC [23]. This study aimed to describe 
the epidemiology and the characteristics of IMD cases 
in Cyprus, including the most prevalent serogroups 
causing disease, and to study the association of sev-
eral risk factors with a fatal outcome. It also discusses 




This is a retrospective study of all cases of IMD diag-
nosed in Cyprus (the Government-controlled area), 
between 1 January 2004 and 31 December 2018.
The population of Cyprus between 2004 and 2018 
ranged from 733,067 in 2004 to 854,802 at end of 2016 
[24].
Definitions
The EU case definition defines a confirmed case of IMD 
as any case that fulfils the laboratory criteria for diag-
nosis of IMD. These are any of the following: isolation 
of  N. meningitidis  from a normally sterile site or from 
purpuric skin lesions or detection of nucleic acid of N. 
meningitidis from a normally sterile site or from purpuric 
skin lesions or detection of N. meningitidis antigen or 
Gram-negative diplococci in cerebrospinal fluid (CSF) 
[25]. Because the N. meningitidis antigen test does not 
discriminate between serogroup W and Y, cases of W 
and Y are sometimes processed together as W/Y in this 
manuscript.
Clinically compatible cases refer to cases with typical 
clinical features strongly suggestive of meningococcal 
disease such as fever, stiff neck, petechial or purpuric 
rash, septic shock and/or CSF findings suggestive of 
meningitis, but without bacteriological confirmation 
[26].
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For further analysis of the cases, the presence of blood-
stream infection or meningococcaemia/septicaemia 
was defined as a positive blood culture and/or positive 
blood PCR test [27].
Presence of meningitis only was defined as the clinical 
picture of meningitis without the typical rash but with 
positive cultures/PCR, Gram stain or rapid antigen test 
for N. meningitidis from CSF [26].
Surveillance of invasive meningococcal disease
In Cyprus, surveillance of IMD is based on the man-
datory notification system as every practicing physi-
cian who diagnoses a new case of IMD must notify the 
public health authorities by completing a notification 
form. The operational body responsible for processing 
all information on communicable diseases is the Unit 
for Surveillance and Control of Communicable Diseases 
(USCCD). This Unit administratively belongs to the 
Directorate of the Medical and Public Health Services 
of the Ministry of Health. In addition to confirmed 
cases, each physician has to notify each suspect case 
by telephone directly to the staff of the Unit within 24 
h of examining the patient, so that appropriate public 
health measures are promptly taken. The notification 
form collects demographic data on the case such as 
age, sex, residence, any epidemiologic link to other 
cases and whether the case was imported.
All invasive strains isolated in regional laborato-
ries were referred to the Microbiology Department of 
Nicosia General Hospital where serogrouping of each 
isolate is performed. Meningococcal isolates were 
cultured on Chocolate Columbia Agar (OXOID Ltd, 
Basingstoke, UK) and incubated at 37 °C and 5–10% 
CO2  for 24 h. Serogroups were identified by a slide 
agglutination test (Remel Europe Ltd., Dartfort, UK) 
[28]. The laboratory of the Nicosia General Hospital 
notified the serogroup results both to the USCCD and 
to the clinicians who manage the IMD case. Isolates 
were then sent to the National Meningitis Reference 
Laboratory in Athens, Greece for further molecular 
typing. Furthermore, for culture-negative suspected 
biological samples, a multiplex PCR assay was carried 
out for identification and typing of N. meningitidis [29]. 
Genogroup was determined by multiplex PCR targeting 
specific capsule group genes, as described previously 
[30].
All meningococcal isolates belonging to a sero-/
genogroup were characterised by finetyping (multi-
locus sequence typing and PorA and FetA typing), as 
described previously [31], using the PubMLST.org/
neisseria database (http://pubmlst.org/ neisseria/). 
Sequence types (ST) were defined and grouped into 
clonal complexes (ccs). PorA genotyping for varia-
ble regions 1 and 2 (VR1 and VR2) was performed as 
described previously [32] and compared with the vari-
able sequences in the Neisseria PorA database (http://
pubmlst.org/neisseria/PorA/). Similarly, the FetA vari-
able region was also obtained for all typeable isolates, 
as previously described [33] and compared with vari-
able sequences in the Neisseria FetA database (http://
pubmlst.org/neisseria/FetA/). All results are submit-
ted to The European Surveillance System (TESSy) on an 
annual basis.
In 2017, a molecular method was also introduced 
at the microbiology department of Nicosia General 
Hospital, for the detection of  N. meningitidis  and 
other pathogens in CSF specimens. The method is 
an automated multiplex RT-PCR, using the Film Array 
Meningitis/Encephalitis (ME) Panel Analyzer (BIOFIRE 
diagnostics, LLC, Salt Lake City, US) applied for detect-
ing pathogens directly from CSF specimens. The 
method only detects species and not serogroups or 
other characteristics [34].
The CSF specimens from cases from all districts in the 
Government-controlled area of Cyprus which are clini-
cally compatible with bacterial meningitis are sent to 
this laboratory in order to be processed by this tech-
nique. Since the introduction of this new methodol-
ogy, the yield of detection of meningococcal disease 
has further increased, particularly in culture-negative 
cases. The CSF specimens are referred for molecular 
diagnostics before the result of traditional culture is 
known. Therefore, in some cases there may be posi-
tive molecular as well as traditional culture results for 
a CSF specimen.
When an IMD case is laboratory-confirmed, a second 
more extensive questionnaire on clinical and labora-
tory findings of the case is completed and sent to the 
USCCD by the diagnosing physician. This questionnaire 
includes details on the clinical picture on admission as 
well as the laboratory findings in blood and CSF and 
information on the outcome of the case.
Data collection
For the purposes of this study, data were collected from 
(i) the notification forms and the extensive question-
naires on confirmed and clinically compatible cases 
of IMD kept at the USCCD and (ii) additional data were 
retrieved from patients’ records in the public hospitals 
in cases of existing gaps in clinical information. Data 
between 1998 and 2003 on numbers of cases each year 
were also retrieved from notification forms kept at the 
USCCD.
Study subjects
Patients hospitalised between 1 January 2004 and 31 
December 2018 and diagnosed as confirmed or clini-
cally compatible cases of IMD were included in this 
study. These patients were hospitalised in all five pub-
lic and the two largest private hospitals in Cyprus. The 
catchment area of these hospitals is the whole popu-




Data were analysed using the R statistical software 
version 3.5.1 [35]. Package ggplot2 was used for all 
plots [36]. Univariable logistic regression was used 
to investigate the association between patient-related 
risk factors and death. Models were fit using Firth’s 
bias reduction method in package logistf to address 
issues of separation [37,38].
Ethical statement
The National Bioethics committee granted exemption 
to this study as this was a retrospective study where 
all data were used anonymously and special care was 
taken to preserve the protection of personal data.
Results
Between 1 January 2004 and 31 December 2018, 54 
cases of IMD were reported to the health authorities of 
Cyprus. A total of 25 cases were male and 29 cases were 
female, with an age range from 19 days to 89 years. The 
mean age of patients was 19.6 years and the median 
age was 14.5 years. Four of these cases were compati-
ble with a strong clinical suspicion for IMD, but without 
laboratory confirmation. In two of the notified cases, 
there was no information on the method of diagnosis. 
A total of 41 of the 54 cases occurred in Cypriot citi-
zens, while the remainder were British citizens (n = 7), 
Eastern European nationals (n = 4), Greek (n = 1) and 
Swedish (n = 1). Seven cases were imported. No sec-
ondary cases were reported. The overall mean annual 
incidence rate was 0.4 cases per 100.000 population, 
ranging from 0.1 in 2011 to 0.8 in 2005 and 2012. The 
incidence rate was highest among children younger 
than 1 year, reaching 7.2 cases per 100,000 popula-
tion in this age group (10 cases). A second peak was 
noted in adolescents aged 15–19 years with 1.4 cases 
per 100,000 population (12 cases). The lowest inci-
dence was observed in 30–59 year-olds (0.06 cases 
per 100,000 population; three cases).  Figure 1  shows 
the distribution of IMD by age group.
As shown in  Figure 2, the incidence of meningococcal 
disease in Cyprus decreased between 1998 and 2011. 
However, after a peak in 2012, the mean incidence 
appeared to have reached a higher plateau, fluctuating 
between 0.2 and 0.6 cases per 100,000.
Figure 1






















Serogroup B was the most frequent serogroup caus-
ing disease, accounting for 24 of 40 cases with known 
serogroup (Figure 2). Moreover, serogroup B repre-
sented an even higher proportion of cases in age 
groups with a higher incidence of meningococcal dis-
ease: five of seven cases in infants, eight of 11 cases in 
children younger than 5 years and seven of 10 cases in 
15–19 years-olds. Serogroup C accounted for only four 
of 40 cases overall, similar to serogroup W. Overall, 
serogroups W and Y together accounted for a total of 
eight of the 40 cases and for three of the four fatalities 
that were caused by strains with known serogroup.
Serogrouping was not performed before 2004. Even 
between 2004 and 2011, unknown serogroups were 
recorded in 10 of 27 cases. In these cases, the isolates 
were not sent to the reference laboratory for sero-
grouping (Figure 2). However, between 2012 and 2018, 
unknown serogroups were reported in only four of 27 
cases of IMD.
Seasonal distribution
Figure 3 shows the distribution of all cases per month 
after exclusion of the imported cases. While cases 
were spread throughout the year, a large proportion of 
them (23/47) occurred between January and April.
Clinical characteristics
Table 1  shows the epidemiological as well as clinical 
characteristics of cases. The ratio of male to female 
cases was 1:1.2. Nearly half of the cases for whom 
this information was available were classified as both 
meningitis and septicaemia (25/53), while 16 cases 
were diagnosed as only meningitis and 12 cases as 
only septicaemia. Culture of sterile body fluids such as 
blood or CSF confirmed the diagnosis in 31 of 52 cases 
(Table 1) and molecular methods (PCR) in nine cases. 
One case was diagnosed by both culture and PCR. No 
cases were diagnosed by culturing the skin lesions. 
Five cases were diagnosed by CSF latex agglutination 
and two cases by CSF Gram stain. Four cases were only 
diagnosed based on the clinical picture as compatible 
with IMD.
Risk factors for death
Among 48 cases with known outcome, five patients 
died (10.4%). Results of the univariable logistic regres-
sion investigating factors associated with death are 
shown in  Table 2. This analysis found no statisti-
cally significant association between sex and death 
Figure 2












































NG: non-groupable; Unk: unknown (samples for which the isolate was not sent to the reference laboratory for serogrouping.
Bars: distribution of serogroups among cases for each year; black line: total number of cases for each year. The individual number of cases 
per serogroup is indicated on the bars.
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(p = 0.219). On the other hand, when age was used as 
a numerical dependent variable, there was an increase 
in the odds of death with increasing age, which was 
statistically significant (p = 0.050). The presence of 
meningitis vs meningococcaemia decreased the odds 
of death 17 times (p = 0.007). In terms of factors rele-
vant to the clinical presentation of the patients, time 
from onset of symptoms to admission, white blood 
cell count on admission and lethargy or confusion on 
admission were examined, but no statistically signifi-
cant associations were found. Y or W serogroup were 
the cause of the disease in three of four fatal cases 
where the serogroup was determined and the associa-
tion between these serogroups and death was statisti-
cally significant (p = 0.032).
Discussion
In this study we describe and analyse the epidemiology 
and clinical characteristics of IMD in Cyprus. The mean 
incidence of IMD in Cyprus was estimated at 0.4 cases 
per 100,000 population over a period of 15 years. This 
estimate is lower than for some other Mediterranean 
countries such as Malta or France and similar to the 
incidence in Greece and Spain [39]. However, the inci-
dence in infants was much higher and was the highest 
of all age groups. This is the case in many countries 
and is believed to be the result of their insufficiently 
developed immune system and the gradual loss of 
the antibodies acquired via the placenta [40]. A sec-
ond high peak in incidence was noted in adolescents, 
which is in agreement with the epidemiology of IMD in 
most other countries [5].
The incidence of meningococcal disease in Cyprus 
decreased between 1998 and 2011. However, after a 
peak in 2012, the mean incidence appeared to have 
reached a higher plateau. This small upward trend in 
the incidence of cases after 2012 may have partly been 
due to increased awareness among physicians of their 
responsibility to notify cases. During that year, the 
USCCD ran an awareness campaign directed at phy-
sicians, which included talks at several medical con-
ferences. At the same time, national guidelines were 
issued on the notification and laboratory investigation 
Figure 3














Imported cases (n = 7) are not included in the figure.
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of cases. Further to this, the Reference Laboratory at 
the Nicosia General Hospital employed more sensitive 
molecular techniques for the detection of pathogens 
in new cases after 2011. Before 2017, specimens were 
sent to the Meningococcal Reference Laboratory in 
Athens, Greece for molecular diagnosis of suspect IMD 
disease. In 2017, the RT-PCR technique was applied at 
the Microbiology Reference Laboratory in the Nicosia 
General Hospital. It has been well recognised in sev-
eral studies that the use of PCR increases diagnostic 
sensitivity when compared with traditional culture of 
blood or CSF alone. In a study from Ireland, blood cul-
tures were positive in only eight of 39 PCR-confirmed 
cases, partly because of the administration of antibi-
otic treatment before cultures were taken [41]. In the 
UK, 58% of cases were confirmed by PCR only [42].
During the study period in Cyprus serogroup C was a 
rare cause of meningococcal disease restricted in sin-
gle cases and no more cases were detected after 2013. 
A decrease in serogroup C disease was also noted in 
other European countries as a result of the high MenC 
vaccine coverage in children [5,12].
Serogroup B appeared to be the most frequent sero-
group causing disease in the population of Cyprus 
especially in infants and adolescents. This is the case 
as in many other European countries [5]. The National 
Immunization Technical Advisory Group (NITAG) 
assessed the potential introduction of meningococcal 
B vaccine into the national immunisation programme at 
the end of 2018. Based on various factors such as the 
low incidence of meningococcal disease in Cyprus so 
far, it was decided to offer immunisation with MenB at 
Table 1
Characteristics of cases of invasive meningococcal disease, 
Cyprus, 2004–2018 (n = 54)















Culture and PCR 1/52 1.9
Latex agglutinationd 5/52 9.6
CSF Gram stain 2 /52 3.8
Clinical diagnosis 4/52 7.7
CSF: cerebrospinal fluid.
a In one case, the clinical picture (i.e. meningitis or septicaemia) 
was unknown.
b Outcome was unknown for six cases.
c In one case, both culture and PCR were positive. In two cases, no 
information was given about the method of diagnosis.
d In cases of positive latex agglutination in CSF, serogroup Y 
cannot be discriminated from serogroup W. Therefore, the two 
serogroups were counted together.
Table 2
Univariable logistic regression analysis of possible risk 
factors for death in invasive meningococcal disease cases, 
Cyprus, 2004–2018 (n = 54)
Risk factor Odds ratio 95% confidence interval p value
Presence of meningitis
No Ref
Yes 0.08 0.01–0.61 0.007
Age (years) 1.03 1.00–1.07 0.050
Sex
Female Ref
Male 0.32 0.04–2.31 0.219
White blood cell count on admission
High Ref
Normal/low 3.54 0.45–27.9 0.198
Unknown 4.27 0.32–56.21 0.256
Confusion or lethargy on admission
No Ref 
Yes 7.34 0.33–162.09 0.116
Unknown 43.00 1.33–1389.16 0.008
Onset of symptoms to admission 
No Ref
Unknown 17.00 0.67–434.16 0.053
Yes 3.60 0.46–28.11 0.190
Serogroup
B Ref
C 1.59 0.01–35.55 0.793
W or Y 9.12 1.21–110.02 0.032
Non-
groupable 2.87 0.02–73.39 0.578
Unknown 1.87 0.14–25.09 0.608
Ref: reference category.
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this stage only to groups at high risk for severe menin-
gococcal disease, such as people with asplenia and 
other immunocompromising conditions. This decision 
is compatible with the one taken by NITAGs in many 
other European countries thus far [43]. The possible 
introduction of the vaccine will be reevaluated in 2020, 
as new scientific data come to light.
Serogroups W and Y appeared to cause a consider-
able proportion of cases of meningococcal disease. 
The recent increase in these two serogroups was also 
noted in other European countries [15,16]. In addition, 
these two serogroups were associated with a higher 
risk of death and accounted for three of the four fatal 
cases caused by a known serogroup. Therefore, the 
NITAG decided in 2019 that the MenACWY vaccine will 
be given in the national immunisation schedule at the 
age of 12 months instead of the monovalent MenC vac-
cine, and also to male adolescents at the age of 18 
years before joining the armed forces. MenACYW is 
also given to prospective students at colleges or uni-
versities in Cyprus, in other European countries and in 
the US [44,45].
A substantial proportion of cases occurred in win-
ter and the early spring months, especially between 
January and April. The increased seasonal incidence 
in winter months was in agreement with the observed 
epidemic waves in the past i.e. between 1936 and 1937. 
At that time, large epidemic waves of IMD in Cyprus 
were associated with cold wet weather, which was con-
sidered to result in overcrowding indoors. Epidemics 
of seasonal influenza were also found to be associ-
ated with the peak of the epidemic waves of IMD [46]. 
Respiratory viruses in general and influenza viruses 
specifically have been associated with increased num-
bers of IMD cases [47]. It has been reported that influ-
enza A virus neuraminidase may have a potential role 
in facilitating meningococcal adhesion to influenza 
virus-infected epithelial cells through interaction with 
sialic acid-containing meningococcal capsules [48].
The case fatality ratio for IMD in Cyprus remains sub-
stantial as is the case in most other high-income coun-
tries [5,11]. Beyond serogroups W and Y, the only other 
risk factor associated with increased mortality was 
increasing age. This factor was also noted in a number 
of other studies [10,11,26]. The presence of meningitis 
vs meningococcaemia/septicaemia decreased the odds 
of death by 17 times. This finding was in agreement 
with similar findings in other population series and 
may be explained by an assumption that in the case 
of meningitis, the infection and resulting inflammation 
is restricted mainly to the nervous system and spares 
other tissues [11,26].
The main limitation of this study is its retrospective 
character. However, because of the questionnaire that 
was completed with clinical information and submit-
ted to the USCCD when a new case was diagnosed, 
adequate information was available on all cases of 
IMD. Another limitation is that there were gaps in clini-
cal data regarding mortality as clinical outcome in 11% 
of cases. A third limitation is the small number of IMD 
cases overall, which limited statistical power when 
risk factors for mortality were analysed and prohib-
ited multi-variable regression analysis. These could 
explain why clinical parameters on admission such as 
the presence of confusion, the low or normal number of 
white blood cells or the short duration between onset 
of symptoms and admission to hospital could not be 
shown to be statistically significant risk factors for the 
outcome death, although they were shown to be asso-
ciated with increased risk of death in other studies [11]. 
Another limitation which prevents us from fully assess-
ing the impact of immunisation programmes is the dual 
scheme of immunisation providers which operated until 
early 2019, i.e. the public and private sector and the 
resulting differences in the availability of vaccines. It 
is, however, important to say that since 2019, both sec-
tors of healthcare providers have been integrated under 
the National Health Service Organization. Vaccines are 
now determined by the National Immunisation commit-
tee and are given free of charge to all population.
Conclusions
Although rare, IMD remains an important cause of 
morbidity and mortality among the Cypriot popula-
tion. Introduction of vaccines, as well as appropri-
ate preventive measures taken when a new case is 
diagnosed, have resulted in a decreased incidence of 
disease. It appears that serogroup B accounts for an 
important proportion of new cases especially in the 
high incidence age groups infants and adolescents. 
This occurred despite the fact that meningococcal B 
vaccine had already been offered by the private sec-
tor to a substantial yet unknown percentage of chil-
dren. Serogroups Y and W have also become important 
as causes of IMD in the population and were the the 
main serogroups causing mortality. The introduction of 
MenACWY at the age of 12 months and also before join-
ing the army is expected to decrease IMD caused by 
these serogroups.
Continuous monitoring of IMD in Cyprus remains an 
important tool in the prevention and control of this 
disease and will help in the evaluation of the immuni-
sation programmes. National guidelines for the preven-
tion, early recognition and management of the disease 
have to be prepared and disseminated to the health-
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